Engineered recombinant collagen-like protein and bionik made therefrom

3D生物打印在制造组织工程和其他生物医学应用的支架方面具有优势，因为它具有快速制造，高精度和定制设计能力。然而，3D生物打印所需的生物墨水材料，特别是包含细胞以构建细胞支架的生物墨水，并没有像3D生物打印机那样迅速发展。 该项目的目标是开发一种基于模块化，定制的生物活性胶原蛋白样蛋白（BCP）的生物墨水。蛋白质和生物墨水将通过降低生物墨水生产成本，促进生物墨水的可打印性和原位交联能力，改善生物墨水的生物相容性和安全性，以及扩大3D打印生物材料的功能和实用性来解决3D生物打印的关键障碍。 该项目完善了渥太华大学正在申请专利的BCP技术，该技术最近由我们的实验室开发。该项目的成功执行将使研究人员和生命科学公司，包括那些可能作为未来商业化合作伙伴的公司，更接近实现3D生物打印在再生医学应用中的巨大潜力，并最终为医疗应用本身的发展做出贡献。******

3D bioprinting has advantages in the manufacture of scaffolds for tissue engineering and other biomedical applications due to its rapid-fabrication, high-precision, and customized design capabilities. However, bioink materials required for 3D bioprinting, particularly bioinks that incorporate cells to build cellular scaffolds, have not developed as quickly as 3D bioprinters. The goal of this project is to develop a bioink based on a modular, tailor-made bioactive collagen-like protein (BCP). The protein and bioink will address key hurdles in 3D bioprinting by reducing bioink production costs, facilitating bioink printability and in situ cross-linking capabilities, improving bioink biocompatibility and safety, and broadening the functionality and utility of 3D-printed biomaterials. This project refines the University of Ottawa's patent pending BCP technology, recently developed by our lab. Successful execution of this project will bring researchers and life science companies, including those who may serve as future commercialization partners, one step closer to realizing the significant potential of 3D bioprinting for regenerative medicine applications, and eventually contribute to the development of medical applications themselves. ******